Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

LRR protein RNH1 dampens the inflammasome activation and is associated with adverse clinical outcomes in COVID-19 patients

Autor: Bombaci, Giuseppe, Sarangdhar, Mayuresh Anant, Andina, Nicola, Tardivel, Aubry Bernard Maurice, Chi-Wang Yu, Eric, Mackie, Gillian M., Pugh, Matthew, Ozan, Vedat Burak, Banz, Yara, Spinetti, Thibaud, Hirzel, C��dric, Youd, Esther, Schefold, Joerg C., Taylor, Graham, Gazdhar, Amiq, Bonadies, Nicolas, Angelillo-Scherrer, Anne, Schneider, Pascal, Maslowski, Kendle M., Allam, Ramanjaneyulu

Publikováno v: Bombaci, Giuseppe; Sarangdhar, Mayuresh Anant; Andina, Nicola; Tardivel, Aubry Bernard Maurice; Chi-Wang Yu, Eric; Mackie, Gillian M.; Pugh, Matthew; Ozan, Vedat Burak; Banz, Yara; Spinetti, Thibaud; Hirzel, Cédric; Youd, Esther; Schefold, Joerg C.; Taylor, Graham; Gazdhar, Amiq; Bonadies, Nicolas; Angelillo-Scherrer, Anne; Schneider, Pascal; Maslowski, Kendle M. and Allam, Ramanjaneyulu (26 August 2021). LRR protein RNH1 dampens the inflammasome activation and is associated with adverse clinical outcomes in COVID-19 patients (In Press) (bioRxiv). Cold Spring Harbor Laboratory 10.1101/2021.04.12.438219

Inflammasomes are cytosolic innate immune sensors of pathogen infection and cellular damage that induce caspase-1 mediated inflammation upon activation. Although inflammation is protective, uncontrolled excessive inflammation can cause inflammatory d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3b8f21ecf123d61ff8e5a3f861078bf

Salmonella cancer therapy metabolically disrupts tumours at the collateral cost of T cell immunity.

Autor: Copland A; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK. a.copland@bham.ac.uk., Mackie GM; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK., Scarfe L; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK., Jinks E; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK., Lecky DAJ; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK., Gudgeon N; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK.; Institute for Metabolism and Systems Research, University of Birmingham, Birmingham, B15 2TT, UK., McQuade R; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK., Ono M; Department of Life Sciences, Imperial College London, London, SW7 2AZ, UK., Barthel M; Institute of Microbiology, Department of Biology, ETH Zürich, Zürich, 8093, Switzerland., Hardt WD; Institute of Microbiology, Department of Biology, ETH Zürich, Zürich, 8093, Switzerland., Ohno H; Laboratory for Intestinal Ecosystem, RIKEN Institute for Integrative Medical Science, Yokohama, Japan.; Immunobiology Laboratory, Graduate School of Medical Life Science, Yokohama City University, Yokohama, Japan., Hoevenaar WHM; Cancer Research UK Scotland Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK., Dimeloe S; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK.; Institute for Metabolism and Systems Research, University of Birmingham, Birmingham, B15 2TT, UK., Bending D; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK., Maslowski KM; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK. kendle.maslowski@glasgow.ac.uk.; Institute for Metabolism and Systems Research, University of Birmingham, Birmingham, B15 2TT, UK. kendle.maslowski@glasgow.ac.uk.; Cancer Research UK Scotland Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK. kendle.maslowski@glasgow.ac.uk.; School of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Glasgow, G61 1QH, UK. kendle.maslowski@glasgow.ac.uk.

Publikováno v: EMBO molecular medicine [EMBO Mol Med] 2024 Nov 18. Date of Electronic Publication: 2024 Nov 18.